SAR131675 is primarily used in research settings as a selective inhibitor of the VEGFR-3 (Vascular Endothelial Growth Factor Receptor-3) tyrosine kinase. It is particularly valuable in studies focused on understanding lymphangiogenesis, the process by which new lymphatic vessels form from pre-existing ones. By inhibiting VEGFR-3, SAR131675 helps researchers investigate the role of this receptor in lymphatic system development and function, as well as its implications in diseases such as lymphedema and cancer metastasis. Additionally, it is utilized in preclinical studies to explore potential therapeutic strategies targeting lymphatic-related disorders, including blocking tumor-associated lymphatic growth to prevent cancer spread. Its specificity makes it a useful tool for dissecting VEGFR-3 signaling pathways in cellular and animal models.